A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer.
Liu, J., Chiang, H.C., Xiong, W., Laurent, V., Griffiths, S.C., Dulfer, J., Deng, H., Sun, X., Yin, Y.W., Li, W., Audoly, L.P., An, Z., Schurpf, T., Li, R., Zhang, N.(2023) J Immunother Cancer 11
- PubMed: 37328286 
- DOI: https://doi.org/10.1136/jitc-2023-006720
- Primary Citation of Related Structures:  
8PE9 - PubMed Abstract: 
Immune exclusion (IE) where tumors deter the infiltration of immune cells into the tumor microenvironment has emerged as a key mechanism underlying immunotherapy resistance. We recently reported a novel role of discoidin domain-containing receptor 1 (DDR1) in promoting IE in breast cancer and validated its critical role in IE using neutralizing rabbit monoclonal antibodies (mAbs) in multiple mouse tumor models.
Organizational Affiliation: 
Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA.